What is the present valuation and projected CAGR of the fecal microbiota transplantation (fmt) market?
The fecal microbiota transplantation (FMT) market size has grown strongly in recent years. It will grow from $0.85 $ billion in 2024 to $0.91 $ billion in 2025 at a compound annual growth rate (CAGR) of 7.2%. The growth in the historic period can be attributed to growing awareness of gut microbiome, expanding therapeutic applications, increasing personalized medicine, adoption in gastroenterology practices, increasing number of clinical trials and increasing funding and investments.
The fecal microbiota transplantation (FMT) market size is expected to see strong growth in the next few years. It will grow to $1.19 $ billion in 2029 at a compound annual growth rate (CAGR) of 6.9%. The growth in the forecast period can be attributed to increasing incidence of clostridium difficile infections (CDI), rising prevalence of inflammatory bowel diseases, increasing research and development activities, rising geriatric population, and expanding healthcare infrastructure. Major trends in the forecast period include the development of standardized protocols for donor screening, stool preparation, advances in microbiome analysis, improved stool processing technologies, novel delivery methods, and the development of synthetic or standardized microbiota-based products.
Get Your Free Sample of The Global Fecal Microbiota Transplantation (FMT) Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=19430&type=smp
What key drivers have fueled the fecal microbiota transplantation (fmt) market’s development over the years?
The rising prevalence of gastrointestinal disorders is expected to propel the growth of the fecal microbiota transplantation (FMT) market going forward. Gastrointestinal (GI) disorders refer to a wide range of conditions that affect the gastrointestinal tract, which includes the esophagus, stomach, small intestine, large intestine (colon), rectum, and anus. The rise in gastrointestinal disorders is due to increased stress, sedentary lifestyles, and higher consumption of processed foods. Fecal microbiota transplantation is used in gastrointestinal disorders to restore healthy gut bacteria, particularly for treating recurrent Clostridioides difficile infections. For instance, in 2023, according to Crohn’s and Colitis Canada, a Canada-based non-profit organization, the number of people in Canada with IBD is increasing rapidly, from 322,600 in 2023 (0.8% of the population) to 470,000 in 2035 (1.1% of the population). In 2023, 11,000 people will be diagnosed (1 every 48 minutes), and by 2035, this will rise to 14,000 (1 every 38 minutes). Therefore, the rising prevalence of gastrointestinal disorders drives the growth of the fecal microbiota transplantation (FMT) market.
What is the segmentation for the fecal microbiota transplantation (fmt) market?
The fecal microbiota transplantation (FMT) market covered in this report is segmented –
1) By Type: Fermentation, Fresh, Cryopreservation
2) By Donor Type: Stool-Derived, Fecal-Derived, Whole-Microbiome Derived
3) By Indication: Clostridioides Difficile Infection, Inflammatory Bowel Disease, Metabolic Syndrome, Other Indications
4) By Administration Route: Oral, Rectal, Nasogastric, Colon Capsule
5) By End-User: Hospitals, Specialty Clinics, Other End-Users
Subsegments:
1) By Fermentation: Fermented FMT Products, Fermented Capsules, Fermented Liquids, In-House Fermentation Techniques
2) By Fresh: Fresh Stool Samples, Fresh FMT Capsules, Fresh FMT Solutions for In-Hospital Use, Freshly Prepared FMT for Outpatient Use
3) By Cryopreservation: Cryopreserved Stool Samples, Cryopreserved FMT Capsules, Cryopreserved Liquid FMT, Long-Term Storage Solutions for Cryopreserved FMT
Order your report now for swift delivery
Who are the most influential companies in the fecal microbiota transplantation (fmt) market?
Major companies operating in the fecal microbiota transplantation (FMT) market are Ferring Pharmaceuticals, Johns Hopkins Medicine, Seres Therapeutics, Taconic Biosciences, Enterome, Rebiotix Inc., Finch Therapeutics Group Inc., Locus Biosciences, Yeda Research and Development Co. Ltd., Microbiotica Limited, CosmosID Inc., AOBiome, Synthetic Biologics Inc., Osel Inc., OpenBiome, Asia Microbiota Bank, Taymount Clinic, MicroBiome Therapeutics LLC, MaaT Pharma SA, Kallyope
What are the top industry trends projected to impact the fecal microbiota transplantation (fmt) market?
Major companies operating in the fecal microbiota transplantation (FMT) market are focusing on developing innovative solutions, such as microbiota-based live biotherapeutics, to enhance treatment efficacy for gastrointestinal disorders. Microbiota-based live biotherapeutics refer to live microorganisms used as therapeutic agents to restore or modify the gut microbiome for treating various diseases. For instance, in November 2022, Ferring Pharmaceuticals, a Switzerland-based biopharmaceutical company, received US Food and Drug Administration (FDA) approval for REBYOTA (fecal microbiota, live-jslm), a novel first-in-class microbiota-based live biotherapeutic indicated for the prevention of recurrence of Clostridioides difficile infection (CDI) in individuals 18 years of age and older, following antibiotic treatment for recurrent CDI. REBYOTA is indicated for preventing Clostridioides difficile (C. difficile) infection recurrence in individuals 18 years of age and older following antibiotic treatment for recurrent CDI.
What are the major regional insights for the fecal microbiota transplantation (fmt) market, and which region holds the top position?
North America was the largest region in the fecal microbiota transplantation (FMT) market in 2024. The regions covered in the fecal microbiota transplantation (FMT) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
What Does The Fecal Microbiota Transplantation (FMT) Market Report 2025 Offer?
The fecal microbiota transplantation (fmt) market research report from The Business Research Company offers global market size, growth rate, regional shares, competitor analysis, detailed segments, trends, and opportunities.
Fecal microbiota transplantation (FMT) is a medical procedure where a healthy donor’s fecal material is transplanted into a recipient’s gastrointestinal tract to restore the balance of beneficial microorganisms in the gut. This procedure is typically used to treat conditions where the gut microbiota is disrupted, such as recurrent clostridium difficile infection (CDI) that does not respond to standard treatments.
Purchase the exclusive report now to unlock valuable market insights:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=19430
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
